Can semaglutide cause someone to feel detached from themselves or their surroundings? A new report describes both experiences in one adult taking the drug for obesity. The timing gave her clinicians a reason to suspect a connection. The report leaves two questions unanswered: whether semaglutide caused her symptoms and whether people who take it experience them more often.
The case report, published online November 17 in JCEM Case Reports, raises a more specific question than whether GLP-1 medicines affect mood. It describes episodes of dissociation. Knowing what the paper means by that term helps explain why the larger safety studies offer only partial context.
What feeling detached meant in this case
Depersonalization describes feeling detached from yourself. Derealization is the sense that familiar surroundings feel unreal or dreamlike. The patient described both. She understood that her surroundings were real, even when they felt dreamlike. That detail helped the authors characterize the episodes.
The published clinical timeline describes a 42-year-old woman with obesity and no reported history of psychiatric illness. Her first episode came about a week after her second injection at a higher dose. Over the following ten days, the episodes became more frequent and disrupted her work. The clinicians checked for other explanations. Among the findings they reported were a normal glucose reading during an observed episode, unrevealing brain imaging and a negative urine toxicology screen.
Why the timeline raised suspicion
The treating team discontinued semaglutide. According to the follow-up in the case report, episodes became less frequent within a week and had resolved by four weeks without psychiatric medication. She reported no recurrence at three months. The team did not restart semaglutide, so there is no observation of whether the episodes would have returned with another exposure.
The authors used the Naranjo adverse-reaction scale to organize the evidence. On that checklist, the onset after exposure and the improvement after withdrawal both added points. The authors also credited their assessment of other possible causes and their clinical observations. The resulting score of six fell in the scale’s “probable” category. That category summarizes their assessment of this case. It supplies neither a numerical probability that the medicine was responsible nor an estimate of how often the symptoms occur. With one patient and no comparison group, the report cannot show what would have happened over the same weeks without a change in treatment.
What the larger safety studies measured
A post hoc analysis of four randomized STEP trials compared semaglutide with placebo using questionnaires for depressive symptoms and suicidal thoughts and behavior. Investigators also asked open-ended questions about adverse events. The published main analysis contains no separate estimate for depersonalization or derealization. The depression questionnaire measures depressive symptoms. It cannot tell us how often people felt detached from themselves or their surroundings. Our guide to randomized and real-world evidence explains how the choice of outcome limits what a comparison can answer.
An FDA review published in January 2026 addressed suicidal thoughts and behavior, the subject of its request to remove a warning from certain GLP-1 labels. It did not address whether semaglutide causes dissociation. The U.S. Wegovy prescribing information reviewed for this article does not list depersonalization or derealization. That tells readers what the label says today. It takes more evidence to establish whether a drug contributes to a symptom or to estimate its frequency.
What to bring to a conversation about new symptoms
Someone experiencing unfamiliar or distressing episodes can describe them in everyday language to a healthcare professional. Useful details include what felt different, when it began, how long it lasted, how often it returned and whether it interfered with work or daily activities. A record of medication changes around that time can help put the episodes in context. A person does not have to decide whether a medicine caused a symptom before bringing it up. In the U.S., patients and health professionals can also report suspected serious reactions through FDA MedWatch.
For background on the medicine, see our semaglutide profile. Our article on tracking weight and mood covers a separate question about depressive symptoms in routine care. What would advance the dissociation question is a set of independently documented cases or a study that specifically measures these symptoms in a defined group and provides a comparison.



